- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00846807
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
Observational Cohort Study to Evaluate the Safety and Efficacy of Pradaxa (Dabigatran Etexilate) for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery in a Routine Clinical Setting.
연구 개요
상태
정황
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Bad Homburg, 독일
- 1160.85.04924 Boehringer Ingelheim Investigational Site
-
Bayreuth, 독일
- 1160.85.04926 Boehringer Ingelheim Investigational Site
-
Berlin, 독일
- 1160.85.04903 Boehringer Ingelheim Investigational Site
-
Bochum, 독일
- 1160.85.04931 Boehringer Ingelheim Investigational Site
-
Breitenbrunn, 독일
- 1160.85.04930 Boehringer Ingelheim Investigational Site
-
Chemnitz, 독일
- 1160.85.04923 Boehringer Ingelheim Investigational Site
-
Erlangen, 독일
- 1160.85.04947 Boehringer Ingelheim Investigational Site
-
Fürth, 독일
- 1160.85.04945 Boehringer Ingelheim Investigational Site
-
Garmische-Partenkirchen, 독일
- 1160.85.04912 Boehringer Ingelheim Investigational Site
-
Gelnhausen, 독일
- 1160.85.04922 Boehringer Ingelheim Investigational Site
-
Gelsenkirchen, 독일
- 1160.85.04917 Boehringer Ingelheim Investigational Site
-
Günzburg, 독일
- 1160.85.04949 Boehringer Ingelheim Investigational Site
-
Hachenburg, 독일
- 1160.85.04927 Boehringer Ingelheim Investigational Site
-
Hamburg, 독일
- 1160.85.04910 Boehringer Ingelheim Investigational Site
-
Hannover, 독일
- 1160.85.04906 Boehringer Ingelheim Investigational Site
-
Hof, 독일
- 1160.85.04920 Boehringer Ingelheim Investigational Site
-
Kamp-Linfort, 독일
- 1160.85.04916 Boehringer Ingelheim Investigational Site
-
Kassel, 독일
- 1160.85.04939 Boehringer Ingelheim Investigational Site
-
Koblenz, 독일
- 1160.85.04929 Boehringer Ingelheim Investigational Site
-
Landstuhl, 독일
- 1160.85.04909 Boehringer Ingelheim Investigational Site
-
Lübben, 독일
- 1160.85.04944 Boehringer Ingelheim Investigational Site
-
Mainz, 독일
- 1160.85.04935 Boehringer Ingelheim Investigational Site
-
Marburg, 독일
- 1160.85.04902 Boehringer Ingelheim Investigational Site
-
Markgröningen, 독일
- 1160.85.04934 Boehringer Ingelheim Investigational Site
-
Marktheidenfeld, 독일
- 1160.85.04918 Boehringer Ingelheim Investigational Site
-
Merseburg, 독일
- 1160.85.04941 Boehringer Ingelheim Investigational Site
-
Minden, 독일
- 1160.85.04952 Boehringer Ingelheim Investigational Site
-
München, 독일
- 1160.85.04943 Boehringer Ingelheim Investigational Site
-
München, 독일
- 1160.85.04946 Boehringer Ingelheim Investigational Site
-
Nürnberg, 독일
- 1160.85.04904 Boehringer Ingelheim Investigational Site
-
Olsberg, 독일
- 1160.85.04913 Boehringer Ingelheim Investigational Site
-
Pfortzheim, 독일
- 1160.85.04932 Boehringer Ingelheim Investigational Site
-
Rosenheim, 독일
- 1160.85.04901 Boehringer Ingelheim Investigational Site
-
Rostock, 독일
- 1160.85.04915 Boehringer Ingelheim Investigational Site
-
Rostock, 독일
- 1160.85.04928 Boehringer Ingelheim Investigational Site
-
Rotenburg/Fulda, 독일
- 1160.85.04936 Boehringer Ingelheim Investigational Site
-
Schwarzenbruck, 독일
- 1160.85.04905 Boehringer Ingelheim Investigational Site
-
Sylt, 독일
- 1160.85.04914 Boehringer Ingelheim Investigational Site
-
Wertheim, 독일
- 1160.85.04933 Boehringer Ingelheim Investigational Site
-
Wiesbaden, 독일
- 1160.85.04921 Boehringer Ingelheim Investigational Site
-
Wismar, 독일
- 1160.85.04938 Boehringer Ingelheim Investigational Site
-
Worms, 독일
- 1160.85.04907 Boehringer Ingelheim Investigational Site
-
Würzburg, 독일
- 1160.85.04940 Boehringer Ingelheim Investigational Site
-
Würzburg, 독일
- 1160.85.04948 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kungälv, 스웨덴
- 1160.85.4603 Boehringer Ingelheim Investigational Site
-
Motala, 스웨덴
- 1160.85.4601 Boehringer Ingelheim Investigational Site
-
Solleftea, 스웨덴
- 1160.85.4604 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Madrid, 스페인
- 1160.85.3404 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1160.85.3406 Boehringer Ingelheim Investigational Site
-
Malaga, 스페인
- 1160.85.3405 Boehringer Ingelheim Investigational Site
-
Pamplona, 스페인
- 1160.85.3407 Boehringer Ingelheim Investigational Site
-
Valencia, 스페인
- 1160.85.3401 Boehringer Ingelheim Investigational Site
-
Zaragoza, 스페인
- 1160.85.3402 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Croom, 아일랜드
- 1160.85.35301 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Basildon, 영국
- 1160.85.04405 Boehringer Ingelheim Investigational Site
-
Gateshead, 영국
- 1160.85.04406 Boehringer Ingelheim Investigational Site
-
Halifax, 영국
- 1160.85.04402 Boehringer Ingelheim Investigational Site
-
London, 영국
- 1160.85.04404 Boehringer Ingelheim Investigational Site
-
Luton, 영국
- 1160.85.04403 Boehringer Ingelheim Investigational Site
-
Wigan, 영국
- 1160.85.04401 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Graz, 오스트리아
- 1160.85.4308 Boehringer Ingelheim Investigational Site
-
Klagenfurt, 오스트리아
- 1160.85.4309 Boehringer Ingelheim Investigational Site
-
Linz, 오스트리아
- 1160.85.4303 Boehringer Ingelheim Investigational Site
-
Linz, 오스트리아
- 1160.85.4304 Boehringer Ingelheim Investigational Site
-
St. Johann/Tirol, 오스트리아
- 1160.85.4305 Boehringer Ingelheim Investigational Site
-
Stolzalpe, 오스트리아
- 1160.85.4312 Boehringer Ingelheim Investigational Site
-
Wels, 오스트리아
- 1160.85.4307 Boehringer Ingelheim Investigational Site
-
Wien, 오스트리아
- 1160.85.4301 Boehringer Ingelheim Investigational Site
-
Wien, 오스트리아
- 1160.85.4302 Boehringer Ingelheim Investigational Site
-
Wien, 오스트리아
- 1160.85.4310 Boehringer Ingelheim Investigational Site
-
Wien, 오스트리아
- 1160.85.4311 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bari, 이탈리아
- 1160.85.03911 Boehringer Ingelheim Investigational Site
-
Firenze, 이탈리아
- 1160.85.03905 Boehringer Ingelheim Investigational Site
-
Genova, 이탈리아
- 1160.85.03904 Boehringer Ingelheim Investigational Site
-
Jesi (an), 이탈리아
- 1160.85.03906 Boehringer Ingelheim Investigational Site
-
Latina, 이탈리아
- 1160.85.03914 Boehringer Ingelheim Investigational Site
-
Mantova, 이탈리아
- 1160.85.03901 Boehringer Ingelheim Investigational Site
-
Ome (bs), 이탈리아
- 1160.85.03913 Boehringer Ingelheim Investigational Site
-
Roma, 이탈리아
- 1160.85.03907 Boehringer Ingelheim Investigational Site
-
Torino, 이탈리아
- 1160.85.03909 Boehringer Ingelheim Investigational Site
-
Vimercate (mi), 이탈리아
- 1160.85.03910 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Koscierzyna, 폴란드
- 1160.85.4805 Boehringer Ingelheim Investigational Site
-
Lodz, 폴란드
- 1160.85.4804 Boehringer Ingelheim Investigational Site
-
Otwock, 폴란드
- 1160.85.4803 Boehringer Ingelheim Investigational Site
-
Piekary Slaskie, 폴란드
- 1160.85.4802 Boehringer Ingelheim Investigational Site
-
Swiebodzin, 폴란드
- 1160.85.4806 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Angers, 프랑스
- 1160.85.3306A Boehringer Ingelheim Investigational Site
-
Bois Guillaume Cédex, 프랑스
- 1160.85.3318A Boehringer Ingelheim Investigational Site
-
Bordeaux, 프랑스
- 1160.85.3333A Boehringer Ingelheim Investigational Site
-
Caen Cedex 9, 프랑스
- 1160.85.3310A Boehringer Ingelheim Investigational Site
-
Clermont-Ferrand cedex 1, 프랑스
- 1160.85.3311A Boehringer Ingelheim Investigational Site
-
Creteil, 프랑스
- 1160.85.3315A Boehringer Ingelheim Investigational Site
-
DIJON Cédex, 프랑스
- 1160.85.3305A Boehringer Ingelheim Investigational Site
-
Illkirch, 프랑스
- 1160.85.3304A Boehringer Ingelheim Investigational Site
-
Le Havre, 프랑스
- 1160.85.3334A Boehringer Ingelheim Investigational Site
-
Les Lilas, 프랑스
- 1160.85.3324A Boehringer Ingelheim Investigational Site
-
Lille cedex, 프랑스
- 1160.85.3309A Boehringer Ingelheim Investigational Site
-
Lyon, 프랑스
- 1160.85.3307A Boehringer Ingelheim Investigational Site
-
Marseille, 프랑스
- 1160.85.3325A Boehringer Ingelheim Investigational Site
-
Metz, 프랑스
- 1160.85.3323A Boehringer Ingelheim Investigational Site
-
Nantes Cédex 2, 프랑스
- 1160.85.3321A Boehringer Ingelheim Investigational Site
-
Paris, 프랑스
- 1160.85.3303A Boehringer Ingelheim Investigational Site
-
Paris, 프랑스
- 1160.85.3320A Boehringer Ingelheim Investigational Site
-
Paris cedex 10, 프랑스
- 1160.85.3301A Boehringer Ingelheim Investigational Site
-
Paris cedex 14, 프랑스
- 1160.85.3302A Boehringer Ingelheim Investigational Site
-
Pierre Bénite cedex, 프랑스
- 1160.85.3308A Boehringer Ingelheim Investigational Site
-
Poitiers Cédex, 프랑스
- 1160.85.3322A Boehringer Ingelheim Investigational Site
-
Saint Etienne Cédex 2, 프랑스
- 1160.85.3319A Boehringer Ingelheim Investigational Site
-
Saint Saulve, 프랑스
- 1160.85.3317A Boehringer Ingelheim Investigational Site
-
Toulouse Cedex 9, 프랑스
- 1160.85.3314A Boehringer Ingelheim Investigational Site
-
Toulouse Cédex 9, 프랑스
- 1160.85.3313A Boehringer Ingelheim Investigational Site
-
Vannes Cédex, 프랑스
- 1160.85.3331A Boehringer Ingelheim Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion criteria:
Patients of 18 years of age or above undergoing elective total hip or knee replacement surgery who consent in writing to their participation in this observational study
Exclusion criteria:
All patients who should not be treated with Pradaxa 220 mg according to the European Summary of Product Characteristics (SPC): age of > 75 years, renal impairment (creatinine clearance <50 ml/min), patients with concomitant therapy of amiodarone, elevated liver enzymes > 2 upper limit of normal (ULN) and/or hepatic impairment or liver disease expected to have any impact on survival, anaesthesia with post operative indwelling epidural catheters, hypersensitivity to dabigatran etexilate or to any of the excipients, active clinically significant bleeding, organic lesion at risk of bleeding, spontaneous or pharmacological impairment of haemostasis except for the above included patients groups, concomitant treatment with quinidine
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
---|
Patients 75 years or younger
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Patients With Major Bleeding Events (MBE) During Treatment Period
기간: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Major bleeding events were defined according to the modified McMaster criteria, and were classified by the investigator as Major bleeding event or Any bleeding event.
The criteria for MBE's were: fatal; clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected; clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected; symptomatic retroperitoneal, intracranial, intraocular or intraspinal; requiring treatment cessation; leading to re-operation
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of Patients With Symptomatic Venous Thromboembolic Events (sVTE) and All Cause Mortality
기간: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
The co-primary efficacy variable sVTE was defined as the composite of documented symptomatic proximal and distal deep vein thrombosis (DVT) and documented symptomatic non-fatal pulmonary embolism (PE).
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Patients With Major Extra-surgical Site Bleedings
기간: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
|
Volume of Wound Drainage (Post-operative)
기간: From end of surgery (before first dosing) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Total volume of wound drainage is calculated as sum of volume drainage from end of surgery until first dose of Pradaxa plus volume drainage from first dose of Pradaxa and onwards.
|
From end of surgery (before first dosing) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of Patients With Single Components of Composite of sVTE and All-cause Mortality
기간: From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
혈전색전증에 대한 임상 시험
-
Beijing Friendship Hospital알려지지 않은대장암 환자에서 Perioperiative Venous Thromboembolism(VTE)의 발생률